ArticleJournal of thoracic disease2026
Preoperative fractional exhaled nitric oxide in differentiating pulmonary nodules and pathological examination of non-small cell lung cancer: a retrospective cohort study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer remains the leading cause of cancer-related mortality worldwide, and preoperative differentiation of pulmonary nodules remains challenging. We aimed to investigate the clinical value of preoperative fractional exhaled nitric oxide (FENO) in distinguishing benign pulmonary nodules from malignant pulmonary nodules and characterizing its relationship with pathological features of non-small cell lung cancer (NSCLC). Methods: After exclusions from 1,046 consecutive patients, 550 patients were included and classified into malignant (NSCLC) and benign groups based on postoperative pathological examination. Using the Mann-Whitney U test, FENO levels were compared between the two groups. Receiver operating characteristic (ROC) curve analysis was conducted with the optimal cutoff value determined based on the Youden index. Multivariate binary logistic regression analysis was conducted to assess the independent association of FENO with the malignant behavior of NSCLC. In the malignant group, FENO levels were compared across pathological types, tumor-node-metastasis (TNM) stages, and programmed death-ligand 1 (PD-L1) expression groups using the Mann-Whitney U test and the Kruskal-Wallis H test. Subsequently, multivariate linear regression analysis was conducted to explore the independent association between FENO and PD-L1 expression. Results: Preoperative levels of FENO were significantly higher in the malignant group than in the benign group {median [interquartile range (IQR)]: 23 [18-29] Conclusions: Preoperative levels of FENO demonstrated moderate diagnostic value for malignant nodules. It also exhibited exploratory associations with the squamous histological subtype and PD-L1 expression. Prospective, multicenter validation is needed before clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.